Monday 30 July 2012, 1:33PM
Media release from AlphaMed
Durham, NC (July 2012) - A team of researchers in Japan has
discovered that VD3, a super-active form of Vitamin D, boosts stem
cells to enhance and maintain their ability to induce hair growth.
This new study, reported in STEM CELLS Translational Medicine,
builds upon previous studies that have demonstrated how dermal
papilla cells (DPCs) can stimulate epithelial stem cells to become
"We had already discovered how VD3 increases the transforming
growth factor TGF-ß2 and alkali-phosphatase activity - two
essential features of hair-inducing DPCs. This time we focused on
VD3's therapeutic potency and values for hair regeneration," said
Kotaro Yoshimura, M.D. "The results suggest that it may be useful
in expanding human DPCs with good quality, and help establish a DPC
transplantation therapy for growing hair."
Yoshimura and Noriyuki Aoi, M.D., both of the University of Tokyo
(UT) School of Medicine, led scientists from UT, Osaka University
and the Japan Science and Technology Agency in the investigation.
After running more tests on how VD3 affected another crucial
element for hair growth called Wnt10b gene expression, they
collected DPCs from volunteers who had undergone facelifts,
incubated the DPCs with VD3 and then grafted them onto hairless
skin samples taken from rats.
"We found that treating the dermal papilla cells with VD3
significantly enhanced the growth of new hair over that of the
control group," Dr. Aoi said. "We also observed a better rate of
maturation of the follicles. In other words, the hair grew thicker
and lasted longer."
"This study may contribute to the development of a cell-based
therapy for hair regeneration," said Anthony Atala, MD, Editor of
STEM CELLS Translational Medicine and director of the Wake Forest
Institute for Regenerative Medicine. "The research team shows the
potential impact of vitamin D to boost the capacity of certain
cells in the skin to form hair."
About STEM CELLS Translational Medicine: STEM CELLS TRANSLATIONAL
MEDICINE (SCTM), published by AlphaMed Press, is a monthly
peer-reviewed publication dedicated to significantly advancing the
clinical utilization of stem cell molecular and cellular biology.
By bridging stem cell research and clinical trials, SCTM will help
move applications of these critical investigations closer to
accepted best practices. www.StemCellsTM.com
About AlphaMed Press: Established in 1983, AlphaMed Press with
offices in Durham, NC, San Francisco, CA, and Belfast, Northern
Ireland, publishes two other internationally renowned peer-reviewed
journals: STEM CELLS® (www.StemCells.com), celebrating its 30th
anniversary in 2012, is the world's first journal devoted to this
fast paced field of research. The Oncologist®
(www.TheOncologist.com), also a monthly peer-reviewed publication,
entering its 17th year, is devoted to community and hospital-based
oncologists and physicians entrusted with cancer patient care. All
three journals are premier periodicals with globally recognized
editorial boards dedicated to advancing knowledge and education in
their focused disciplines.